Search Results
Jan 06, 2026, 08:00 ET Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
BOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President and Chief Executive Officer, will present at
More news about: Edgewise Therapeutics
Jan 05, 2026, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., Jan. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Dec 24, 2025, 08:00 ET Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
BOULDER, Colo., Dec. 24, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, cardiac sarcomere modulator,
More news about: Edgewise Therapeutics
Dec 02, 2025, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Nov 20, 2025, 08:00 ET Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors.
More news about: Edgewise Therapeutics
Nov 12, 2025, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Nov 10, 2025, 08:00 ET Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Nov 07, 2025, 08:00 ET Edgewise Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences:
More news about: Edgewise Therapeutics
Nov 06, 2025, 08:00 ET Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
BOULDER, Colo., Nov. 6, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2025 and recent business highlights.
More news about: Edgewise Therapeutics
Nov 03, 2025, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Oct 02, 2025, 16:01 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Oct 02, 2025, 08:00 ET Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th International Annual Congress of the World Muscle
More news about: Edgewise Therapeutics